Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $82 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $82.
April 16, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Intra-Cellular Therapies with a maintained price target of $82.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst like Ami Fadia from Needham suggests strong confidence in Intra-Cellular Therapies' future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in ITCI's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100